论文部分内容阅读
近日在西雅图召开的关于病毒的会议上，联合国对抗艾滋病项目很高兴地看到一系列最新的关于抗逆转录病毒药物在预防艾滋病毒新感染效用的临床研究成果。
在2015逆转录病毒和机会感染会议上，两个单独的关于暴露前预防药物的研究结果表明在预防男男性行为的新型艾滋病感染上该药物有86%的功效。
第三项研究表明对于所谓血清不一致的配偶一个人携带艾滋病病毒，另一人没有使用暴露前预防药物以及抗逆转录病毒治疗法来预防艾滋病毒阴性一方同阳性一方结合而患艾滋病的有效率为96%。
联合国艾滋病规划署执行理事Michel Sidibé称，“这些新的研究成果是在为进行男男性行为的男性以及血清不一致的配偶们有效预防艾滋病的努力中的重大突破，这些研究成果是及时且重要的，将有助于推动到2030年结束艾滋病蔓延目标的实现。”
英国的一项包括500名因进行男男性行为而患艾滋病风险较高的男性的研究显示，每天服用替诺福韦及恩曲他滨的人比不服用药物的感染艾滋病率低86%。相同的结果也出现在法国及加拿大进行的类似研究中，参与者们服食四片替诺福韦及恩曲他滨，分别在性行为前后食用两片。
在肯尼亚和乌干达的另一项研究中，暴露前预防药物被用于艾滋病阴性方，抗逆转录病毒药物则用于艾滋病阳性方。研究结果显示，这样的结合产生了96%的功效，表明暴露前预防药物是有效的“结合”治疗方式，在艾滋病阳性方开始接受治疗与其传播病毒几率降低的过程中，用来减少艾滋病的新感染率。
The United Nations programme working to combat HIV/AIDS welcomed recently the results of a number of recent clinical studies of the effects of antiretroviral medicines on preventing new HIV infections， which were presented at a conference on viruses held in Seattle.
At the 2015 Conference on Retroviruses and Opportunistic Infections （CROI）， the results of two separate studies on pre-exposure prophylaxis （PrEP） medicines showed 86 per cent efficacy in preventing new HIV infections among men who have sex with men.
A third study showed that in the so-called serodiscordant couples – where one partner has HIV and the other does not – access to PrEP for the HIV-negative person combined with access to antiretroviral therapy for the HIV-positive person was 96 per cent effective in preventing new infections.
"These new results are a significant breakthrough in advancing efforts to provide effective HIV prevention options to men who have sex with men and to serodiscordant couples，" said Michel Sidibé， Executive Director of UNAIDS. "The results are timely and important and will advance global efforts to end the AIDS epidemic by 2030."
A study in the United Kingdom， involving 500 men who have sex with men at higher risk of HIV infection， found that those taking a daily pill of the medicines tenofovir and emtricitabine were 86 per cent less likely to become infected with HIV than those involved in the study not taking the medicines. The same effect was found in a similar study conducted in France and Canada， where participants took four tablets of tenofovir and emtricitabine， two before and two after sexual intercourse.
In another study， conducted in Kenya and Uganda， PrEP was used on the HIV-negative partner， while antiretrovirals were used on the HIV-positive partner. The results， which showed that the combination produced 96 per cent efficacy， suggested that PrEP could be a highly effective "bridge" treatment to reduce new infections in the period between when a HIV-positive person begins treatment and their risk of transmitting the virus reduces.
http：//www.un.org/apps/news/story.asp？NewsID=50171#.VPfyYT9rE_w
在2015逆转录病毒和机会感染会议上，两个单独的关于暴露前预防药物的研究结果表明在预防男男性行为的新型艾滋病感染上该药物有86%的功效。
第三项研究表明对于所谓血清不一致的配偶一个人携带艾滋病病毒，另一人没有使用暴露前预防药物以及抗逆转录病毒治疗法来预防艾滋病毒阴性一方同阳性一方结合而患艾滋病的有效率为96%。
联合国艾滋病规划署执行理事Michel Sidibé称，“这些新的研究成果是在为进行男男性行为的男性以及血清不一致的配偶们有效预防艾滋病的努力中的重大突破，这些研究成果是及时且重要的，将有助于推动到2030年结束艾滋病蔓延目标的实现。”
英国的一项包括500名因进行男男性行为而患艾滋病风险较高的男性的研究显示，每天服用替诺福韦及恩曲他滨的人比不服用药物的感染艾滋病率低86%。相同的结果也出现在法国及加拿大进行的类似研究中，参与者们服食四片替诺福韦及恩曲他滨，分别在性行为前后食用两片。
在肯尼亚和乌干达的另一项研究中，暴露前预防药物被用于艾滋病阴性方，抗逆转录病毒药物则用于艾滋病阳性方。研究结果显示，这样的结合产生了96%的功效，表明暴露前预防药物是有效的“结合”治疗方式，在艾滋病阳性方开始接受治疗与其传播病毒几率降低的过程中，用来减少艾滋病的新感染率。
The United Nations programme working to combat HIV/AIDS welcomed recently the results of a number of recent clinical studies of the effects of antiretroviral medicines on preventing new HIV infections， which were presented at a conference on viruses held in Seattle.
At the 2015 Conference on Retroviruses and Opportunistic Infections （CROI）， the results of two separate studies on pre-exposure prophylaxis （PrEP） medicines showed 86 per cent efficacy in preventing new HIV infections among men who have sex with men.
A third study showed that in the so-called serodiscordant couples – where one partner has HIV and the other does not – access to PrEP for the HIV-negative person combined with access to antiretroviral therapy for the HIV-positive person was 96 per cent effective in preventing new infections.
"These new results are a significant breakthrough in advancing efforts to provide effective HIV prevention options to men who have sex with men and to serodiscordant couples，" said Michel Sidibé， Executive Director of UNAIDS. "The results are timely and important and will advance global efforts to end the AIDS epidemic by 2030."
A study in the United Kingdom， involving 500 men who have sex with men at higher risk of HIV infection， found that those taking a daily pill of the medicines tenofovir and emtricitabine were 86 per cent less likely to become infected with HIV than those involved in the study not taking the medicines. The same effect was found in a similar study conducted in France and Canada， where participants took four tablets of tenofovir and emtricitabine， two before and two after sexual intercourse.
In another study， conducted in Kenya and Uganda， PrEP was used on the HIV-negative partner， while antiretrovirals were used on the HIV-positive partner. The results， which showed that the combination produced 96 per cent efficacy， suggested that PrEP could be a highly effective "bridge" treatment to reduce new infections in the period between when a HIV-positive person begins treatment and their risk of transmitting the virus reduces.
http：//www.un.org/apps/news/story.asp？NewsID=50171#.VPfyYT9rE_w